^
    Back
    Association details:
    Biomarker:PIK3R1 mutation
    Cancer:Breast Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor) +
    tilarginine (L-NMMA) (pan-NOS inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR 2023
    Title:

    3447 - NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer

    Published date:
    03/15/2023
    Excerpt:
    L-NMMA was synergistic with alpelisib in MpBC cell lines with PIK3CA/PIK3R1 mutations…. In vivo evaluation using MpBC PDX tumors found that L-NMMA augmented the efficacy of alpelisib in reducing tumor volume in PIK3CA-mutated MpBC PDX models….We find that combining L-NMMA and alpelisib is a novel therapeutic strategy to treat MpBC...
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SABCS 2022
    Title:

    NOS inhibition reverses epithelial-to-mesenchymal transition and synergizes with alpelisib in metaplastic breast cancer

    Published date:
    11/22/2022
    Excerpt:
    Combining L-NMMA with alpelisib was synergistic in MpBC cell lines harboring PIK3CA/PIK3R1 mutations (CI< 1)….In vivo evaluation using MpBC PDX tumors found that L-NMMA significantly augmented the efficacy of alpelisib in reducing tumor volume in PIK3CA-mutated MpBC PDX models.